Far-reaching Proposals For Reform On Table at World Health Assembly – But Will Member States Heed The Call? 20/05/2021 Elaine Ruth Fletcher With an agenda that is more packed than ever – and razor sharp political crises from Gaza to Taiwan to Myanmar also coming to the fore – will the upcoming World Health Assembly prove to be the decisive moment that it should be for global health? Now, more than ever perhaps, huge tensions and inequalities […] Continue reading -> New ‘One Health’ Expert Panel to Address Emergence and Spread of Zoonotic Diseases, as Risk of Zoonoses Rises 20/05/2021 Madeleine Hoecklin A new international expert panel launched by four international organisations on Thursday aims to blunt the emergence and spread of zoonotic diseases through better understanding of human, animal, and environmental interactions that enable animal-borne diseases to break into human populations. The One Health High Level Expert Panel will advise the World Health Organization (WHO), […] Continue reading -> Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> ‘IP Monopoly Capitalism’ – A ‘Virus’ To Society During COVID-19 19/05/2021 Raisa Santos Governments and pharmaceutical companies alike must work together in combating the ‘virus of intellectual property (IP) monopolies over COVID-19 vaccines – which further exacerbates inequality and lack of access to vaccines for vulnerable groups. That was the uptake of a group of experts speaking at a webinar Wednesday on “The Virus of IP Monopoly Capitalism”’ […] Continue reading -> Big Pharma Commits to 5-Point Plan to Increase COVID-19 Vaccine Equity 19/05/2021 Kerry Cullinan Major global vaccine manufacturers and biotech companies have committed to a five-point plan to “advance COVID-19 vaccine equity”, focusing on “responsible dose-sharing” and “maximizing production”. They pointed out that, within a few months, vaccine doses had gone from “zero to 2.2 billion” and were predicted to reach 11 billion doses by the end of 2021 […] Continue reading -> Sanofi-GSK Position SARS-CoV2 Candidate Vaccine as Potential ‘Booster’ 18/05/2021 Kerry Cullinan Sanofi and GSK will test their two-dose SARS-CoV2 vaccine candidate as a booster for other vaccines during its phase 3 trial, following a phase 2 trial that showed that it triggered a strong neutralizing antibody response in people previously vaccinated. Those who had already been vaccinated showed a strong response after one jab, indicating that […] Continue reading -> WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
New ‘One Health’ Expert Panel to Address Emergence and Spread of Zoonotic Diseases, as Risk of Zoonoses Rises 20/05/2021 Madeleine Hoecklin A new international expert panel launched by four international organisations on Thursday aims to blunt the emergence and spread of zoonotic diseases through better understanding of human, animal, and environmental interactions that enable animal-borne diseases to break into human populations. The One Health High Level Expert Panel will advise the World Health Organization (WHO), […] Continue reading -> Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> ‘IP Monopoly Capitalism’ – A ‘Virus’ To Society During COVID-19 19/05/2021 Raisa Santos Governments and pharmaceutical companies alike must work together in combating the ‘virus of intellectual property (IP) monopolies over COVID-19 vaccines – which further exacerbates inequality and lack of access to vaccines for vulnerable groups. That was the uptake of a group of experts speaking at a webinar Wednesday on “The Virus of IP Monopoly Capitalism”’ […] Continue reading -> Big Pharma Commits to 5-Point Plan to Increase COVID-19 Vaccine Equity 19/05/2021 Kerry Cullinan Major global vaccine manufacturers and biotech companies have committed to a five-point plan to “advance COVID-19 vaccine equity”, focusing on “responsible dose-sharing” and “maximizing production”. They pointed out that, within a few months, vaccine doses had gone from “zero to 2.2 billion” and were predicted to reach 11 billion doses by the end of 2021 […] Continue reading -> Sanofi-GSK Position SARS-CoV2 Candidate Vaccine as Potential ‘Booster’ 18/05/2021 Kerry Cullinan Sanofi and GSK will test their two-dose SARS-CoV2 vaccine candidate as a booster for other vaccines during its phase 3 trial, following a phase 2 trial that showed that it triggered a strong neutralizing antibody response in people previously vaccinated. Those who had already been vaccinated showed a strong response after one jab, indicating that […] Continue reading -> WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pandemic Treaty & Other New COVID Initiatives Grab Center Stage At World Health Assembly 20/05/2021 Pokuaa Oduro-Bonsrah Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports: The […] Continue reading -> ‘IP Monopoly Capitalism’ – A ‘Virus’ To Society During COVID-19 19/05/2021 Raisa Santos Governments and pharmaceutical companies alike must work together in combating the ‘virus of intellectual property (IP) monopolies over COVID-19 vaccines – which further exacerbates inequality and lack of access to vaccines for vulnerable groups. That was the uptake of a group of experts speaking at a webinar Wednesday on “The Virus of IP Monopoly Capitalism”’ […] Continue reading -> Big Pharma Commits to 5-Point Plan to Increase COVID-19 Vaccine Equity 19/05/2021 Kerry Cullinan Major global vaccine manufacturers and biotech companies have committed to a five-point plan to “advance COVID-19 vaccine equity”, focusing on “responsible dose-sharing” and “maximizing production”. They pointed out that, within a few months, vaccine doses had gone from “zero to 2.2 billion” and were predicted to reach 11 billion doses by the end of 2021 […] Continue reading -> Sanofi-GSK Position SARS-CoV2 Candidate Vaccine as Potential ‘Booster’ 18/05/2021 Kerry Cullinan Sanofi and GSK will test their two-dose SARS-CoV2 vaccine candidate as a booster for other vaccines during its phase 3 trial, following a phase 2 trial that showed that it triggered a strong neutralizing antibody response in people previously vaccinated. Those who had already been vaccinated showed a strong response after one jab, indicating that […] Continue reading -> WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
‘IP Monopoly Capitalism’ – A ‘Virus’ To Society During COVID-19 19/05/2021 Raisa Santos Governments and pharmaceutical companies alike must work together in combating the ‘virus of intellectual property (IP) monopolies over COVID-19 vaccines – which further exacerbates inequality and lack of access to vaccines for vulnerable groups. That was the uptake of a group of experts speaking at a webinar Wednesday on “The Virus of IP Monopoly Capitalism”’ […] Continue reading -> Big Pharma Commits to 5-Point Plan to Increase COVID-19 Vaccine Equity 19/05/2021 Kerry Cullinan Major global vaccine manufacturers and biotech companies have committed to a five-point plan to “advance COVID-19 vaccine equity”, focusing on “responsible dose-sharing” and “maximizing production”. They pointed out that, within a few months, vaccine doses had gone from “zero to 2.2 billion” and were predicted to reach 11 billion doses by the end of 2021 […] Continue reading -> Sanofi-GSK Position SARS-CoV2 Candidate Vaccine as Potential ‘Booster’ 18/05/2021 Kerry Cullinan Sanofi and GSK will test their two-dose SARS-CoV2 vaccine candidate as a booster for other vaccines during its phase 3 trial, following a phase 2 trial that showed that it triggered a strong neutralizing antibody response in people previously vaccinated. Those who had already been vaccinated showed a strong response after one jab, indicating that […] Continue reading -> WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Big Pharma Commits to 5-Point Plan to Increase COVID-19 Vaccine Equity 19/05/2021 Kerry Cullinan Major global vaccine manufacturers and biotech companies have committed to a five-point plan to “advance COVID-19 vaccine equity”, focusing on “responsible dose-sharing” and “maximizing production”. They pointed out that, within a few months, vaccine doses had gone from “zero to 2.2 billion” and were predicted to reach 11 billion doses by the end of 2021 […] Continue reading -> Sanofi-GSK Position SARS-CoV2 Candidate Vaccine as Potential ‘Booster’ 18/05/2021 Kerry Cullinan Sanofi and GSK will test their two-dose SARS-CoV2 vaccine candidate as a booster for other vaccines during its phase 3 trial, following a phase 2 trial that showed that it triggered a strong neutralizing antibody response in people previously vaccinated. Those who had already been vaccinated showed a strong response after one jab, indicating that […] Continue reading -> WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Sanofi-GSK Position SARS-CoV2 Candidate Vaccine as Potential ‘Booster’ 18/05/2021 Kerry Cullinan Sanofi and GSK will test their two-dose SARS-CoV2 vaccine candidate as a booster for other vaccines during its phase 3 trial, following a phase 2 trial that showed that it triggered a strong neutralizing antibody response in people previously vaccinated. Those who had already been vaccinated showed a strong response after one jab, indicating that […] Continue reading -> WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Appeals For Vaccine Donations To Cover Huge COVAX Shortfall 17/05/2021 Kerry Cullinan COVAX has a shortfall of 190 million COVID-19 vaccine doses, and the few manufacturers that have reached agreements with the facility will only deliver later in the year or even in 2022, World Health Organization (WHO) Director Dr Tedros Adhanom Ghebreyesus said on Monday. “Pfizer has committed to providing 40 million doses of vaccines to […] Continue reading -> Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Sustainable COVAX Vaccine Funding & Voluntary Manufacturing Licenses are Better Solutions than IP Waiver, Says IFPMA Head 16/05/2021 Elaine Ruth Fletcher In preparation for the next pandemic, the COVAX global vaccine facility “needs a pot of money, where they can be early movers” in competing for, and securing, vaccine doses. That could help scenarios like the ones seen recently, in which rich countries cornered the market on the first available COVID-19 vaccines, leading to severe shortages […] Continue reading -> COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVID-19 Research & Innovation Forum Calls for Tighter Collaboration in Face of New Virus Variants 14/05/2021 Svĕt Lustig Vijay Researchers have quickly developed an outstanding arsenal of vaccines, treatments and diagnostics to counter COVID-19. But closer global coordination of diverse clinical trials testing the same or similar treatments, extending even to a global platform to pool anonymized patient data, could strengthen and accelerate research findings – especially as emerging variants threaten to unwind gains. […] Continue reading -> Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds 14/05/2021 Madeleine Hoecklin Delaying the second dose of the Pfizer/BioNTech COVID-19 vaccine by 12 weeks could generate antibody responses in those over the age of 80 more than threefold, found a pre-print study published on Friday. The study, conducted by the University of Birmingham and Public Health England, is the first to directly compare the immune response derived […] Continue reading -> Posts navigation Older postsNewer posts